New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting

Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immunotherapy could be an effective therapeutic strategy for this group of diseases. Here, we rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Roulleaux-Dugage, Matthieu, Italiano, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408188/
https://www.ncbi.nlm.nih.gov/pubmed/37553669
http://dx.doi.org/10.1186/s13045-023-01486-6
_version_ 1785086133734998016
author Roulleaux-Dugage, Matthieu
Italiano, Antoine
author_facet Roulleaux-Dugage, Matthieu
Italiano, Antoine
author_sort Roulleaux-Dugage, Matthieu
collection PubMed
description Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immunotherapy could be an effective therapeutic strategy for this group of diseases. Here, we reviewed the latest advances of immunotherapy trials from the 2023 American Society of Clinical Oncology Annual Meeting, including some novel and encouraging combination regimens. Further research is still needed to fully understand the optimal use of these agents in sarcoma treatment.
format Online
Article
Text
id pubmed-10408188
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104081882023-08-09 New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting Roulleaux-Dugage, Matthieu Italiano, Antoine J Hematol Oncol Editorial Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immunotherapy could be an effective therapeutic strategy for this group of diseases. Here, we reviewed the latest advances of immunotherapy trials from the 2023 American Society of Clinical Oncology Annual Meeting, including some novel and encouraging combination regimens. Further research is still needed to fully understand the optimal use of these agents in sarcoma treatment. BioMed Central 2023-08-08 /pmc/articles/PMC10408188/ /pubmed/37553669 http://dx.doi.org/10.1186/s13045-023-01486-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Editorial
Roulleaux-Dugage, Matthieu
Italiano, Antoine
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
title New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
title_full New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
title_fullStr New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
title_full_unstemmed New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
title_short New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
title_sort new immunotherapy strategies for patients with sarcomas: highlights from the 2023 asco annual meeting
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408188/
https://www.ncbi.nlm.nih.gov/pubmed/37553669
http://dx.doi.org/10.1186/s13045-023-01486-6
work_keys_str_mv AT roulleauxdugagematthieu newimmunotherapystrategiesforpatientswithsarcomashighlightsfromthe2023ascoannualmeeting
AT italianoantoine newimmunotherapystrategiesforpatientswithsarcomashighlightsfromthe2023ascoannualmeeting

Ejemplares similares